trans-Myrtanol | 473-01-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: trans-Myrtanol
• 英文别名: cis-Myrtanol；[(1R,2S,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methanol
• CAS: 473-01-8；514-99-8；15358-91-5；15358-92-6；51152-12-6；53369-17-8；73136-30-8；132203-71-5
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: LDWAIHWGMRVEFR-HRDYMLBCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Potassium Channel Modulators
  申请人：Perez-Medrano Arturo

  公开号：US20120122890A1

  公开（公告）日：2012-05-17

  Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein G 1 , R 2 , R 1a , R 1b , X, X 1 , X 2 , X 3 , R x , J, k, n, q, and t are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文披露了式（I）的KCNQ钾通道调节剂，其中G 1 ，R 2 ，R 1a ，R 1b ，X，X 1 ，X 2 ，X 3 ，R x ，J，k，n，q和t如规范中所定义。还描述了包含这些化合物的组合物；以及使用这些化合物和组合物治疗疾病和疾病的方法。
• N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
  申请人：XENON PHARMACEUTICALS INC.

  公开号：US20130317000A1

  公开（公告）日：2013-11-28

  The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables R A , subscript n, ring A, X 2 , L, subscript m, X 1 , B, R 1 , R 2 , R 3 , R 4 , R 5 and R N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  该发明提供了具有一般公式的新化合物：及其药用盐，其中变量RA、下标n、环A、X2、L、下标m、X1、B、R1、R2、R3、R4、R5和RN的含义如本文所述，并含有这种化合物和使用这种化合物和组合物的方法。
• [EN] NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE<br/>[FR] NOUVEAUX COMPOSÉS DE SULFAMATE POUR UNE UTILISATION MÉDICALE
  申请人：SOLVAY PHARM GMBH

  公开号：WO2009050252A1

  公开（公告）日：2009-04-23

  This invention relates to sulfamates of Formula (I), wherein R1 to R3 and n are defined in the claims, having carbonic anhydrase enzyme inhibitory activity, to medicaments comprising these compounds, to pharmaceutical compositions comprising these compounds, and to processes for the preparation of these compounds. The invention is also directed to the use of such compounds, medicaments and compositions, particularly to their use in administering them to patients to achieve a therapeutic effect.

  本发明涉及公式（I）的磺酸盐，其中R1至R3和n在权利要求中定义，具有碳酸酐酶酶抑制活性，以及包含这些化合物的药物、包含这些化合物的制药组合物，以及制备这些化合物的方法。本发明还涉及这些化合物、药物和组合物的使用，特别是在将其用于患者治疗以达到治疗效果方面的使用。
• Sulfamate Compounds and Uses Thereof
  申请人：SCHOEN Uwe

  公开号：US20090104126A1

  公开（公告）日：2009-04-23

  A sulfamate compound corresponding to Formula I wherein R1 to R3 and n have defined meanings, pharmaceutical compositions comprising these compounds; a process for preparing these compounds, and the use of such compounds or compositions to treat or inhibit various disorders or disease states in patients in need thereof by administering to such a patient a therapeutically effective amount of such a compound.

  一种对应于式I的磺酰胺化合物，其中R1到R3和n具有定义的含义，包括这些化合物的制药组合物；制备这些化合物的过程，以及通过向这样的患者施用治疗有效量的这种化合物来治疗或抑制患者需要的各种紊乱或疾病状态的使用这种化合物或组合物。
• SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：US20160009710A1

  公开（公告）日：2016-01-14

  The invention provides compounds having the general formula: [insert formula (I)] (I) and pharmaceutically acceptable salts thereof, wherein the variables R A , subscript n, ring A, X 2 , L, subscript m, X 1 , R 1 , R 2 , R 3 , R 4 , and R N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  该发明提供了具有一般式[插入式(I)的化合物] (I)及其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，R1，R2，R3，R4和RN的含义如此处所述，并提供了含有这些化合物的组合物以及使用这些化合物和组合物的方法。